Antrogen's stem cell therapy phase 3 analysis is entering the final stage, causing the stock price to surge.
According to the Korea Exchange on the 28th, as of 1:14 PM, Antrogen is trading at 76,700 KRW, up 19.28% (12,400 KRW) from the previous day.
At the corporate briefing session on the same day, Antrogen stated, "We will complete the review of the phase 3 data for diabetic foot ulcer in Korea by the end of August at the earliest. If the analysis proceeds smoothly, we plan to proceed with the product approval process."
▶▶ Revealing undervalued stocks about to surge related to stem cell therapy! (Click)
With the recent stock investment boom, interest in similar investment advisory firms is increasing day by day among individual investors, and ㅇㅇ Investment Group has become the center of attention.
ㅇㅇ Investment Group is a company officially registered with the Financial Supervisory Service, with the motto of fairness and transparency, striving to increase investment funds through customized analysis portfolios and continuous analysis for individual investors.
A wise choice for successful investment! Go directly to ㅇㅇ Investment Group homepage ▶Click◀
ㅇㅇ Investment Group consists of experts with over 14 years of analyst experience, providing high-quality investment information generated based on thorough technical and corporate analysis, offering individual investors a wide range of options.
For the economic freedom of individual investors, seize the opportunity for account growth with ㅇㅇ Investment Group, which helps with new visions and future planning!!
Providing customized total solutions for individual investors! ㅇㅇ Investment Group free trial [Go]
Stock codes: Antrogen / Cha Biotech / Interpark / Gold Pacific / Joongang D&M
※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
